|Doctors examine studies on posters at CTOS.|
By Suzie Siegel
The New York City marathon of sarcoma research ended this month, and we will have a series of reports on it.
The annual meeting of the Connective Tissue Oncology Society drew 815 people, making it the largest gathering of sarcoma physicians and scientists that the world has ever seen.
No reporters showed up, even though I sent out PR and begged everyone I know in the area. (I was a newspaper reporter and editor for 18 years before being diagnosed with leiomyosarcoma.) This illustrates the importance of patient advocacy in getting the word out about trends, ideas and research not yet published.
Michael Leahy, MD, a medical oncologist for the Greater Manchester and Oswestry Sarcoma Service at The Christie in England, tweeted the photo above. We were among a handful of people tweeting from the conference.
|Dr. William Tap|
As scientists and physicians search for more targeted treatments, they continue to revise subtypes.
When cases were reclassified, the study indicated that patients whose leiomyosarcoma started in the bone did worse than those in other categories. Chemotherapy given before surgery seemed to help more than chemo afterward, Dr. Picci said.
He also suggested that synovial sarcoma be reclassified because it doesn’t arise from synovial tissue.
|Dr. Jon Trent|
Sosipatros Boikos, MD, medical director of the National Institutes of Health's Pediatric/Wildtype GIST Clinic, presented a multi-institution study of gastrointestinal stromal tumors without KIT or PDGFRA mutations.
The study found the tumors could be divided into three groups. Two resembled the traditional, adult GIST. The other one was different and SDH deficient. Dr. Boikos now refers to wildtype GIST as SDH-deficient GIST, and the audience seemed to agree with the new term.
A study by the Royal Marsden Hospital in London found that the spread of solitary fibrous tumors (SFT) is more predictable than thought. Angelo Paolo Dei Tos, MD, director of oncology and anatomic pathology at the General Hospital of Treviso, Italy, suggested that physicians no longer use the term “benign SFT” because it can metastasize, although at a lower rate than “malignant SFT.”
For more information, see my previous post on reclassifying sarcomas.CTOS has summaries of papers and posters at: http://ctos.org/2013%20CTOS%20AM%20FP%20Complete%20LRRev1030-Large.pdf Searching by your subtype is an easy way to plow through the information, but keep in mind that some summaries don't mention particular subtypes.
Suzie Siegel is a former journalist and longtime Sarcoma Alliance volunteer. The views represented here do not necessarily reflect those of Sarcoma Alliance and nothing here should be taken as medical advice.